Axon Enterprise, Inc $AXON Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Axon Enterprise, owning approximately 0.10% of the company worth $41.39 million after acquiring additional shares.
• Several institutional investors have significantly boosted their holdings in Axon, with GAMMA Investing LLC increasing its stake by nearly 58,725.5% in the 1st quarter.
• Despite recent insider sales, Axon reported a strong quarter, exceeding earnings expectations with $2.12 EPS and a revenue increase of 32.6% year-over-year.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 3.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,702 shares of the biotechnology company's stock after purchasing an additional 2,391 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.10% of Axon Enterprise worth $41,393,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC boosted its stake in Axon Enterprise by 58,725.5% during the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after purchasing an additional 763,431 shares during the last quarter. Jennison Associates LLC raised its position in shares of Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock valued at $322,961,000 after buying an additional 611,418 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Axon Enterprise in the first quarter valued at about $264,796,000. Westfield Capital Management Co. LP raised its position in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after buying an additional 212,931 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock valued at $4,540,005,000 after buying an additional 185,571 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Activity

In related news, insider Jeffrey C. Kunins sold 7,891 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the completion of the sale, the insider directly owned 144,538 shares of the company's stock, valued at approximately $108,417,953.80. This trade represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $831.29, for a total value of $8,312,900.00. Following the sale, the chief executive officer directly owned 3,053,982 shares of the company's stock, valued at $2,538,744,696.78. The trade was a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,865 shares of company stock worth $26,926,433. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Trading Down 0.2%

Shares of AXON stock opened at $728.41 on Friday. The company's 50-day moving average price is $765.93 and its 200-day moving average price is $679.57. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The stock has a market cap of $57.18 billion, a price-to-earnings ratio of 179.85, a PEG ratio of 26.73 and a beta of 1.40. Axon Enterprise, Inc has a twelve month low of $346.71 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company's quarterly revenue was up 32.6% on a year-over-year basis. During the same period last year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on AXON. Raymond James Financial reiterated an "outperform" rating and issued a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Northland Securities set a $800.00 price target on Axon Enterprise in a report on Tuesday, August 5th. JMP Securities increased their price target on Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a report on Tuesday, July 22nd. Needham & Company LLC set a $870.00 price target on Axon Enterprise and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $837.69.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.